Publications by authors named "Adoracion Blanco"
Patients aged 50 or above diagnosed with myeloid neoplasms (MNs) are typically not candidates for germline testing. However, approximately 8% carry pathogenic germline variants. Allogeneic haematopoietic stem cell transplantation (alloHSCT) remains an option for those aged over 50; neglecting germline testing could mask the risk for relative donor cell-derived MN.
View Article and Find Full Text PDFArticle Synopsis
- The association between mature B-cell phenotype and rearrangements in acute lymphoblastic leukemia (ALL) is rare and marks a distinct group of patients with unique characteristics.
- Three pediatric patients with this mature B-cell phenotype were treated at one institution, and their clinical and biological features were reviewed along with an additional 28 cases from the literature.
- Most cases occur in children under 2 years old and are characterized by expressing IgM and abnormal genetic markers, leading to a high relapse rate (48%) and poor clinical outcomes, indicating a need for improved understanding and treatment strategies.
Article Synopsis
- Allogeneic haematopoietic stem cell transplantation is not recommended in the first complete remission for patients with favorable acute myeloid leukaemia (AML) with NPM1 mutations, despite the possibility of relapse.
- The study analyzed 110 patients with favorable NPM1 AML who achieved complete remission after chemo, finding a two-year cumulative incidence of relapse at 17% and overall survival at 81.5%.
- Patients who experienced molecular failure or hematological relapse required further therapy, with a two-year overall survival of 66%, influenced by measurable residual disease levels, indicating that MRD-based intervention improves outcomes in these patients.
One of the most severe complications after successful cancer therapy is the development of therapy-related myeloid neoplasms (t-MN). Constitutional genetic variation is likely to impact on t-MN risk. We aimed to evaluate if polymorphisms in the p53 pathway can be useful for predicting t-MN susceptibility.
View Article and Find Full Text PDFCYP2C9 is a major liver enzyme responsible of the metabolism of many clinically important drugs. The presence of CYP2C9 genetic polymorphisms has been associated with marked interindividual variability in its catalytic activity that could result in drug toxicity. Here we present frequencies of the most common CYP2C9 coding variants CYP2C9*2 (C430T) and CYP2C9*3 (A1075C) in representative samples of four regions from Spain (Basque Country, n=358; Catalonia, n=240; Central Spain, n=190 and Galicia, n=288) and one northern Italian region, (Verona, n=164), which range between 0.
View Article and Find Full Text PDF